NanoFib®

Fenofibrate 145mg (Nano Form)

Innovation for enhanced efficacy
Innovation for better patients' compliance

- **New Nanofib 145mg** provides higher efficacy than the micronized 160mg fenofibrate
- **New Nanofib 145mg** absorption is not affected by food, unlike other fenofibrate formulations
- **New nanofib 145mg** is a once daily treatment and can be administered at anytime of the day
- **New Nanofib 145mg** provides improved adherence to the treatment

According to the National Cholesterol Educational Program (NCEP) Adult Treatment Panel III Guidelines, simplifying treatment regimens is recommended as one of many key components to improve adherence

High Patient Compliance

Greater convenience and simplicity for patients and prescribers

NanoFib®

Fenofibrate 145mg (Nano Form)

Innovative technology at the service of the patient

- **Proven efficacy**
- **25% of patients had more than 10% improvement in their TG levels**
- **11% more patients reach their LDL Goal with the 145mg Nanofib in comparison with the 160mg formulation**
- **Can be taken with or without food**
- **Improved patient compliance**

References:

[1] Nanocrystal technology, drug delivery and clinical applications,
Junghanns and Müller. International Journal of Nanomedicine 2008: 3(3) 295-309

[2] Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia,
Maciejewski S, Hilleman D, Cardiac Center of Creighton University, Omaha, Nebraska, USA. Pharmacotherapy 2008 May; 28(5): 570-5

Before prescribing please consult physicians' circular.

® Registered trade name

Nanofib® manufactured by BPi

- State of the art manufacturing facility
- Certified European GMP
- ISO Certified

CE GMP

Benta Pharma Industries - Dbayeh, Lebanon

NNF 100F LE 9-2010

NanoFib®

Fenofibrate 145mg

(Nano Form)

Innovative Technology at the service of the patient

BPi

NanoFib®

Fenofibrate 145mg (Nano Form)

Innovative Technology for Improving Patient Health

- **Nanocrystal Technology** is one of the key factors for modern drug therapy, now and in the years to come[1]
- **Nanocrystal Technology** offers a new innovative formulation principle for poorly soluble drugs[1]
- **Nanocrystal Technology** offers the following benefits:[1]
  - Enhanced bioavailability
  - Rapid onset of action
  - Reduction of fed/fasted effects
  - Potential dose reduction



NanoFib®

Fenofibrate 145mg (Nano Form)

Innovation with proven efficacy

- New Nanofib 145mg provides improved lipid profile[2]

› Monotherapy:

LDL-C	HDL-C	TGs
↓ -17%	↑ +18%	↓ -44%

› Concomitantly with statins:

LDL-C	HDL-C	TGs
↓ -40%	↑ +23%	↓ -51%

NanoFib®

Fenofibrate 145mg (Nano Form)

Innovation for enhanced efficacy

- **New Nanofib 145mg** provides higher efficacy at a lower dosage than the micronized 160mg fenofibrate[2]

25% of enrolled patients had more than 10% improvement in their TG level

11% had more than 10% improvement in their LDL level

Patient Group	No. (%) of Patients		
	↓ LDL	↑ HDL	↓ TG
≥ 10% improvement			
Statin (n=68)	6 (9)	3 (4)	13 (19)
No statin (n=62)	8 (13)	1 (2)	19 (31)
All patients (n=130)	14 (11)	4 (3)	32 (25)

- **New Nanofib 145mg** brings more patients to NCEP goal than the micronized 160mg fenofibrate[2]

11% additional patients achieved their NCEP treatment goal after switching to 145 mg nanoparticle fenofibrate